Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
On May 24, 2022, Abbott announced the release of limited quantities of EleCare® specialty formulas, aimed at addressing urgent needs for children with severe food allergies. This action comes after U.S. District Court approval to amend a consent decree following a February recall. Abbott plans to restart production at its Sturgis facility on June 4, prioritizing EleCare manufacturing, with consumer availability expected by June 20. The product release is free of charge for affected families, while additional stocks will be produced to meet ongoing demand.
Abbott (NYSE: ABT) presented significant data at EuroPCR 2022, showcasing its minimally invasive heart devices like TriClip™ and Navitor™. Findings revealed that TriClip significantly reduces tricuspid regurgitation, achieving a 98% implant success rate and 71% improvement in TR levels. Navitor's one-year results also demonstrated safety with a 97.5% procedural success rate and only 4.2% all-cause mortality. These outcomes emphasize Abbott's commitment to enhancing patient quality of life through innovative heart solutions.
Abbott has agreed to a consent decree with the FDA regarding its Sturgis, Michigan infant formula plant, enabling a path to resume production. Following FDA approval, Abbott could restart operations within two weeks, leading to product availability on shelves in 6-8 weeks. The CDC found no link between Abbott's products and infant illnesses, and the company continues to import formula from Ireland to address supply shortages. Abbott maintains its full-year 2022 earnings guidance of at least $4.70 per share despite incurring unspecified one-time charges related to the decree.
Abbott (NYSE: ABT) has partnered with Women as One to launch the CLIMB Research program, aimed at training underrepresented physicians in clinical trials. The program will provide six monthly sessions focused on skill development, networking, and knowledge enhancement for diverse cardiologists, including women and minorities. Abbott has invested $150,000 in this initiative, furthering its commitment to diversity in clinical research. This partnership is part of Abbott's broader strategy to increase representation in clinical trials and improve health outcomes in under-resourced communities.
Abbott has received FDA clearance for its Alinity™ m STI Assay, a multiplex test capable of detecting four sexually transmitted infections (STIs) simultaneously: Chlamydia, Gonorrhea, Trichomonas, and Mycoplasma. The test addresses rising STI rates exacerbated by pandemic-related disruptions in routine testing. Utilizing the advanced Alinity m system, this test enhances efficiency in diagnosis and treatment for healthcare providers. Abbott aims to improve accessibility to STI testing, reflecting on the changes in healthcare delivery during the pandemic.
Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas at the U.S. FDA's request, following a recall of some infant formulas. The released products were not part of the February recall and have met safety standards. Patients can obtain these formulas through healthcare providers and referrals. Abbott's Sturgis facility remains under scrutiny, but no link has been found between it and reported infant illnesses. The company is working with the FDA to resume operations, with new production expected in six to eight weeks.
Abbott's PERSIST-END study revealed that 89% of patients with persistent atrial fibrillation (AFib) treated with the TactiCath™ Contact Force Ablation Catheter remained symptom-free for up to 15 months. The study, involving 224 patients, showed significant improvements in quality of life scores and a 53% reduction in healthcare resource utilization post-procedure. Conducted from 2018-2021, the trial met its primary safety and efficacy endpoints, indicating TactiCath SE's effectiveness in managing persistent AFib and enhancing patient outcomes.
Abbott (NYSE: ABT) has launched the Amplatzer™ Steerable Delivery Sheath in the U.S. to assist in sealing the left atrial appendage (LAA) for patients with atrial fibrillation at risk of stroke. This first-of-its-kind system enhances precision and flexibility during procedures using the Amplatzer Amulet™ LAA Occluder, which aims to reduce stroke risk without long-term blood-thinning medications. The sheath features bi-directional steering, an auto-lock function, and a valve to stabilize blood flow, reinforcing Abbott's commitment to innovation in structural heart therapies.
Abbott (NYSE: ABT) announced results from a meta-analysis of 75 studies indicating its FreeStyle Libre system significantly reduces glycated hemoglobin (HbA1c) in adults with type 1 and type 2 diabetes. After three months, HbA1c levels decreased by 0.53% for type 1 and 0.45% for type 2 diabetes, with reductions sustained for up to 24 months for type 1 and 12 months for type 2. The findings highlight the importance of access to glucose monitoring technology for insulin-using individuals with type 2 diabetes, as it provides similar benefits to those with type 1.
On April 27, 2022, Abbott, CamDiab, and Ypsomed announced a partnership to develop an integrated automated insulin delivery (AID) system targeting diabetes management. This innovative system will combine Abbott's FreeStyle Libre 3 sensor, CamDiab's CamAPS FX algorithm, and Ypsomed's mylife YpsoPump. By enhancing glucose monitoring and insulin delivery, the trio aims to improve health outcomes for diabetes patients, particularly in Europe. Development is expected to conclude by the end of 2022, with commercialization anticipated to follow shortly after.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
